Home Proteases HCV Protease

HCV Protease

Other Proteases Related Inhibitors

Proteasome HIV Protease Thrombin MMP Cysteine Protease Serine Protease Tyrosinase Glutaminase PAD Neprilysin
Cat.No. Product Name Information Product Use Citations Product Validations
S1538 Telaprevir Telaprevir is an HCV NS3-4A serine protease inhibitor with IC50 of 0.35 μM.
JHEP Rep, 2025, 7(5):101328
J Virol, 2024, e0192123.
bioRxiv, 2023, 2023.11.22.568224
Verified customer review of Telaprevir
S1482 Daclatasvir (BMS-790052) Daclatasvir (BMS-790052, EBP883) is a highly selective inhibitor of HCV NS5A with EC50 of 9-50 pM, for a broad range of HCV replicon genotypes and the JFH-1 genotype 2a infectious virus in cell culture. Phase 3.
Structure, 2025, S0969-2126(25)00193-5
J Med Virol, 2024, 96(7):e29787
EMBO Mol Med, 2024, 16(4):870-884
Verified customer review of Daclatasvir (BMS-790052)
S1183 Danoprevir Danoprevir is a peptidomimetic inhibitor of the NS3/4A protease of hepatitis C virus (HCV) with IC50 of 0.2-3.5 nM, inhibition effect for HCV genotypes 1A/1B/4/5/6 is ~10-fold higher than 2B/3A. Phase 2.
Nat Commun, 2025, 16(1):1087
Genes Dev, 2025, 10.1101/gad.353081.125
Cell Rep, 2025, 44(8):116127
Verified customer review of Danoprevir
S1480 Lomibuvir (VX-222) Lomibuvir (VX-222, VCH-222) is a novel, potent and selective inhibitor of HCV polymerase with IC50 of 0.94-1.2 μM. This compound is 15.3-fold less effective for mutant M423T, and 108-fold less effective for mutant I482L. Phase 2.
Cell Death Discov, 2022, 8(1:446)
J Virol, 2022, jvi0190621
Sci Rep, 2021, 11(1):19443
Verified customer review of Lomibuvir (VX-222)
S3733 Boceprevir Boceprevir (EBP 520, SCH 503034) is an oral, direct acting hepatitis C virus (HCV) protease inhibitor with Ki value of 14 nM for NS3. It is used in combination with other antiviral agents in the treatment of chronic hepatitis C, genotype 1.
Eur J Med Chem, 2024, 268:116202
Int J Mol Sci, 2024, 25(11)5767
SLAS Discov, 2024, S2472-5552(24)00043-1
S4935 Asunaprevir Asunaprevir is an orally bioavailable inhibitor of the hepatitis C virus enzyme serine protease NS3 that is necessary for protein processing required for viral replication.
Nat Commun, 2025, 16(1):3800
Int J Mol Sci, 2023, 10.3390/ijms242115535
Nature, 2022, 604(7904):146-151
S3728 Grazoprevir Grazoprevir anhydrous (MK5172) is a Hepatitis C Virus NS3/4A Protease inhibitor with IC50 values of 7pM, 4pM, and 62pM for HCV genotype 1a, 1B, and 4 respectively.
Nucleic Acids Res, 2025, 53(2)gkae1319
Cell Res, 2024, 34(1):31-46
Cell Rep, 2021, 35(7):109133
S5062 Daclatasvir Dihydrochloride Daclatasvir is an orally available antiviral agent that inhibits the NS5A region of the hepatitis C virus (HCV) used for the treatment of chronic HCV genotype 1 and 3 infection.
Commun Biol, 2022, 5(1):154
J Antimicrob Chemother, 2021, 76(7):1874-1885
Med Mol Morphol, 2021, 10.1007/s00795-020-00271-5
S5015 Simeprevir Simeprevir is a competitive, reversible, macrocyclic, noncovalent hepatitis C virus (HCV) NS3/4A protease inhibitor that acts directly against the hepatitis C virus. It has a medium inhibitory concentration (IC50) <13 nM for all HCV NS3/4A enzymes(genotypes 1a, 1b, 2, 4, 5, and 6), but has an IC50 value of 37 nM for genotype 3.
Chemistry, 2022, e202202798.
Cell Rep, 2021, 35(7):109133
Viruses, 2021, 13(2)173
S7579 Ledipasvir (GS5885) Ledipasvir (GS5885) is a HCV NS5A polymerase inhibitor, used for the treatment of hepatitis C virus infection.
Sci Rep, 2021, 11(1):19443
Cancers (Basel), 2019, 11(10)E1407
Biol Pharm Bull, 2019, 10.1248/bpb.b19-00641
Verified customer review of Ledipasvir (GS5885)

Signaling Pathway Map